The global infectious disease diagnostics market size is projected to reach USD 33.1 billion by 2027 from USD 35.5 billion in 2022, at a -1.4% CAGR. Growth in the infectious disease diagnostics industry is mainly driven by factors such as the rising prevalence of infectious diseases and the rising funding for R&D in infectious disease diagnostics. The growing awareness for early disease diagnosis, shift in focus from centralized laboratories to decentralized point-of-care testing and rising technological advancements are factors supporting the growth of this market. On the other hand, an unfavorable reimbursement scenario is expected to limit market growth to a certain extent in the coming years.
The major players in this market are Abbott Laboratories (US), Thermo Fisher Scientific Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMérieux SA (France), Siemens Healthineers AG (Germany), Danaher Corporation (US), Becton, Dickinson and Company (US), PerkinElmer, Inc. (US), Hologic, Inc. (US), QIAGEN N.V. (Netherlands), Grifols S.A. (Spain), DiaSorin S.p.A (Italy), Bio-Rad Laboratories, Inc. (US), Sysmex Corporation (Japan), Ortho Clinical Diagnostics Holdings plc (US), Quidel Corporation (US), Meridian Bioscience (US), Genetic Signatures Ltd. (Australia), OraSure Technologies (US), Trinity Biotech Plc. (Ireland), Chembio Diagnostic Systems (US), Seegene, Inc. (South Korea), Co-Diagnostics (US), ELITechGroup (France), Epitope Diagnostics (US), Trivitron Healthcare (India), Meril Life Sciences Pvt. Ltd. (India), InBios International (US), Vela Diagnostics (Singapore) and Uniogen Oy (Finland).
To know about the assumptions considered for the study download the pdf brochure
Abbott Laboratories accounted for the largest share of the infectious disease diagnostics market in 2021. Abbott Laboratories is a leading player in the infectious disease diagnostics market. The launch of the ID NOW POC testing system by the company is expected to support the growth of its infectious disease diagnostics segment. Abbott Laboratories operates through 291 international and 100 domestic subsidiaries and has a strong geographical presence.
F. Hoffmann-La Roche Ltd. accounted for the second largest share of the infectious disease diagnostics market in 2021. Under its flagship brand- cobas- the company offers a wide variety instruments and reagents that are widely used by end users across the globe. The company also has a wide geographic presence, spanning North America, Europe, the Middle East and Africa, and Asia. This enables the company to cater to customers across the globe. Roche Diagnostics mainly focuses on strategic partnerships & acquisitions to maintain its leading position in the market.
Thermo Fisher Scientific accounted for the third largest share of the infectious disease diagnostics market. It is one of the key players operating in the infectious disease diagnostics market. The company’s leading position in this market can be attributed to its strong sales and distribution network, enabling it to effectively market its products in various countries. Thermo Fisher Scientific invests a significant amount of its revenue in R&D. The high R&D investments enable the company to develop and launch new products in the infectious disease diagnostics market. The company adopts inorganic strategies such as acquisitions to maintain its position in this market. For instance, in 2021, the company acquired Mesa Biotech (US) to broaden its POC molecular diagnostics portfolio for infectious diseases.
Infectious Disease Diagnostics Market by Product (Reagents, Kits, Instrument, Software), Test Type (Lab, POC), Disease (COVID-19, Flu, HAIs, HIV, HPV), Technology (Immunodiagnostics, NGS, INAAT, PCR), End User (Hospitals, Labs) - Global Forecast to 2027
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.SEND ME A FREE SAMPLE